430 results
8-K
EX-99.1
SEEL
Seelos Therapeutics Inc
19 Mar 24
Other Events
4:05pm
neurological diseases that mainly involve the nerve cells (neurons) responsible for controlling voluntary muscle movement. In ALS, both the upper motor neurons
424B3
SEEL
Seelos Therapeutics Inc
15 Mar 24
Prospectus supplement
4:15pm
will be responsible for underwriting discounts or commissions or agent’s commissions. The shares of Common Stock may be sold in one or more transactions at fixed … 2012 to 2013. At SunTrust Robinson Humphrey, he was responsible for coverage of small and mid-cap biotechnology companies with an emphasis on companies
8-K
EX-4.1
ny34ctfw
30 Jan 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-10.2
0u4q6chlm919vhlprb0g
30 Jan 24
Entry into a Material Definitive Agreement
4:01pm
8-K
EX-10.1
0y82895
30 Jan 24
Entry into a Material Definitive Agreement
4:01pm
424B5
9q6tz6skjbqv66hb8
30 Jan 24
Prospectus supplement for primary offering
6:05am
UPLOAD
xaronh7ltro v19p
21 Dec 23
Letter from SEC
12:00am
8-K
EX-4.2
egvuot9es wvi5km
30 Nov 23
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
4:59pm
8-K
EX-4.1
7x524uwdn5f7yyai1s
30 Nov 23
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
4:59pm
8-K
EX-1.1
qs573uywmuamm5yau2
30 Nov 23
Seelos Therapeutics Announces Pricing of $5.55 Million Public Offering
4:59pm
424B5
uoty8f
30 Nov 23
Prospectus supplement for primary offering
4:58pm